General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-30 | 2024-03 | 2.53 | 2.58 | 0.05 | 1.98% |
2024-02-06 | 2023-12 | 2.47 | 2.49 | 0.02 | 0.81% |
2023-11-02 | 2023-09 | -0.08 | 0.1 | 0.18 | 225.00% |
2023-08-08 | 2023-06 | 1.98 | 2.11 | 0.13 | 6.57% |
2023-04-27 | 2023-03 | 1.73 | 1.62 | -0.11 | -6.36% |
2023-02-02 | 2022-12 | 1.83 | 2.09 | 0.26 | 14.21% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-10-08 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-10-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-01 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Morgan Stanley | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-04-14 | ALVAREZ RALPH | Director | 54.03K | Stock Award(Grant) |
2024-02-11 | HAKIM ANAT | General Counsel | 30.48K | Stock Award(Grant) |
2024-04-14 | HEDLEY MARY LYNNE | Director | 1.58K | Stock Award(Grant) |
2024-04-14 | JOHNSON KIMBERLY H | Director | 2.63K | Stock Award(Grant) |
2024-02-15 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 98.90M | Sale |
2024-04-14 | LUCIANO JUAN R | Director | 15.68K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | Lilly Endowment, Inc | 99.98M | 53.70B | 10.53% |
2023-06-29 | Vanguard Group Inc | 69.92M | 32.79B | 7.37% |
2023-06-29 | Blackrock Inc. | 64.45M | 30.23B | 6.79% |
2023-06-29 | PNC Financial Services Group, Inc. | 51.87M | 24.33B | 5.46% |
2023-06-29 | State Street Corporation | 33.88M | 15.89B | 3.57% |
2023-06-29 | FMR, LLC | 32.80M | 15.38B | 3.46% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 26.65M | 12.50B | 2.81% |
2023-06-29 | Vanguard 500 Index Fund | 18.76M | 8.80B | 1.98% |
2023-06-29 | Vanguard/Primecap Fund | 13.35M | 6.26B | 1.41% |
2023-05-30 | Fidelity 500 Index Fund | 8.83M | 3.79B | 0.93% |
2023-08-30 | SPDR S&P 500 ETF Trust | 8.68M | 4.81B | 0.91% |
2023-08-30 | iShares Core S&P 500 ETF | 7.37M | 4.08B | 0.78% |
Dividend | Date |
---|---|
1.3 | 2024-05-15 |
1.3 | 2024-02-15 |
1.3 | 2024-02-14 |
1.13 | 2023-11-14 |
1.13 | 2023-09-08 |
1.13 | 2023-08-14 |
Split | Date |
---|---|
2 : 1 | 1997-10-16 |
2 : 1 | 1995-12-21 |
2 : 1 | 1989-05-01 |
2 : 1 | 1986-01-30 |
$LLY Best Of Breed. See ya at $1,000 Soon!!
$LLY Best of Breed. Top in Weight Loss, Liver Disease, Diabetes, Alzheimer’s and more.
Next Trillion Dollar Company..
$LLY On sale here. Oversold on bad info.
Amgen will need 3 years to get to market.
Lilly has best of breed with a pill coming.
They also will own the market in Alzheimer’s, liver, disease, diabetes, and others.
$1,500 this year.
$LLY Amgen won’t make a cent for years.
Incredibly Undervalued Here. $1,500 eoy
$LLY Best Of Breed Period. Weight Loss, Alzheimer’s, Liver Disease, Diabetes. These are
all Multi Billion Drugs close to approval.
$2,500 in 2 years.
$LLY Amgen is years away with no approvals.
People are stupid and overreacting. Sales here are exploding with several other high value drugs ready for approval and people are selling???
I am buying these dips. See you at $1,200+ eoy
$LLY Laughably Undervalued Here.
BEST OF BREED PERIOD
$LLY Screaming Buy. Best of Breed Period.
https://www.fool.com/investing/2024/05/02/heres-why-eli-lilly-stock-remains-a-screaming-buy/
$LLY open at $785, high of $794 and then drop to $760-$770 range
$LLY Cut to Dumb BearTards Icing the Butthole
“makes no sense”
youre right, it doesnt